Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mahesh Madhavan

Interventional Cardiology New York, NY Medical Doctor

NPI 1104244102 CMS profile 8800412

161 Fort Washington Ave, New York, NY 10032

Open in the dashboard

General payments

$30,536

222 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mahesh Madhavan of New York, NY is reported in the CMS Open Payments database as having received $30,536 across 222 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,881 42
2024 General $3,196 52
2023 General $19,611 54
2022 General $3,276 39
2021 General $1,470 22
2020 General $982 12
2019 General $121 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mahesh Madhavan
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Mahesh Madhavan were reported at $1,881. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Mahesh Madhavan Interventional Cardiology median Middle half National median
2019 $121 $1,097 $329–$3,048 $163
2020 $982 $473 $161–$1,480 $114
2021 $1,470 $677 $233–$1,827 $132
2022 $3,276 $978 $333–$2,724 $149
2023 $19,611 $1,136 $382–$2,986 $160
2024 $3,196 $1,181 $395–$3,326 $164
2025 $1,881 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $16,549 17 payments
  2. Medtronic, Inc. $4,165 40 payments
  3. Abbott Laboratories $2,707 28 payments
  4. Edwards Lifesciences Corporation $2,017 43 payments
  5. AstraZeneca Pharmaceuticals LP $1,097 14 payments
  6. Cardiovascular Systems Inc. $897 7 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $674 16 payments
  8. Abiomed $565 17 payments
  9. Cardiva Medical, Inc. $351 5 payments
  10. CathWorks, Inc. $242 1 payment
  11. Other $1,272 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $15,000 1 payment
  2. Food and Beverage $13,415 208 payments
  3. Travel and Lodging $1,845 11 payments
  4. Education $275 2 payments
Products named General payments · program years 2019–2025
  1. COREVALVE EVOLUT R $3,330 34 payments
  2. SAPIEN 3 Ultra RESILIA $937 22 payments
  3. NAVITOR $894 8 payments
  4. BRILINTA $671 9 payments
  5. Diamondback Coronary $600 5 payments
  6. ONYX FRONTIER $547 4 payments
  7. AVVIGO Guidance System $392 3 payments
  8. JARDIANCE Diabetes $375 3 payments
  9. Impella $342 12 payments
  10. JARDIANCE Diabetes $330 15 payments
  11. Other $5,424 78 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

536

Median for Interventional Cardiology: 2,236

Drug cost

$151,837

Median for Interventional Cardiology: $380,412

Branded share of claims

27.8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 60 $67,966
Entresto Sacubitril/Valsartan Brand 25 $48,734
Jardiance Empagliflozin Brand 24 $31,492
Metoprolol Succinate Generic 68 $867
Atorvastatin Calcium Generic 53 $615
Lisinopril Generic 42 $301
Furosemide Generic 75 $283
Amlodipine Besylate Generic 31 $256
Clopidogrel Clopidogrel Bisulfate Brand 29 $237
Rosuvastatin Calcium Generic 28 $222

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$153,001

Medicare's payments for the services billed

Medicare patients

342

Average age 77

Services billed

1,123

152 women, 190 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 68%
Arthritis 59%
Atrial fibrillation 54%
Diabetes 51%
Chronic kidney disease 48%
COPD 44%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $250
$250 24 —
XARELTO
  • Janssen Pharmaceuticals, Inc $50
$50 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $32
$32 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $9
$9 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $9
$9 25 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

222 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record